IMNN (Imunon) Moat Score: 3/10 (As of Jun. 29, 2026)


IMNN Imunon Inc IMNN
26 GF Score
Price $1.76
! 2 Warning Signs
View Full Analysis

What is Imunon Moat Score?

Imunon IMNN -1.68% 26 Moat Score is 3 as of Jun. 29, 2026. GuruFocus rates IMNN with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,401 Biotechnology companies, Imunon ranks better than 75.52% on this metric.

Imunon has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Imunon has No Moat: Imunon Inc shows weak market presence and lacks significant network effects or customer loyalty. The company has some intellectual property, but it does not translate into a strong competitive advantage. Regulatory barriers and cost advantages are minimal, limiting its moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Imunon might have No Moat - Very weak/transient advantages.

Imunon  (NAS:IMNN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Imunon Moat Score Related Terms

IMNN vs KAPA, HCWB, CURX: Moat Score Comparison

For the Biotechnology subindustry, Imunon's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imunon Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Moat Score distribution charts can be found below:

* The bar in red indicates where Imunon's Moat Score falls into.


IMNN
26GF Score
Imunon Inc IMNN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Imunon (IMNN) has a Moat Score of 3 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Imunon ranks #343 out of 1401 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Imunon's Moat Score too high?
Imunon's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Imunon's value of 3 is 50% above this industry median. Based on the distribution chart, Imunon ranks #343 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Imunon has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Imunon's Moat Score compare to KAPA and HCWB?
According to the Biotechnology industry distribution chart, Imunon ranks #343 out of 1401 companies for Moat Score. This places Imunon in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Imunon's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imunon's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imunon's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imunon stock overvalued right now?
Imunon (IMNN) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Imunon's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Imunon (IMNN), the current Moat Score is 3 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imunon Business Description

Other Exchanges CBO0:Germany
Address 997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
26GF Score

Get the complete analysis for IMNN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.76
Price